University of North Carolina School of Medicine

Department of Pathology and Laboratory Medicine

6109B Neurosciences Research Building



University of North Carolina at Chapel Hill, Chapel Hill, NC

             Ph.D. Pathobiology and Translational Science.  Aug 2011 – May 2017

University of North Carolina at Wilmington, Wilmington, NC

             Bachelor of Science, Honors in Biology.  Aug 2017 – May 2011

             Major: Biology, Minor: Chemistry

Awards and Honors

  1. HHMI-funded UNC Graduate Training Program in Translational Medicine.                         July 2012 – Present

  2. UNC Chapel Hill Robert H. Wagner Scholar in Molecular and Cellular Pathology.             June 2012 – Present

  3. Tied for best second best poster at the 2016 UNC Translational Medicine Symposium.                 April 2016

  4. Best Oral Poster Presentation. Tumor Biology 1 Session. SNO 2015.  Abstract # APTS-55.             Nov 2015

  5. UNC Chapel Hill Graduate Student Mentor Award for Excellence in Mentoring Undergraduates.     May 2015

  6. Travel award to the American Association of Neuropathologists Annual Meeting                              June 2014

  7. Best Clinical/Translational Poster at the UNC Lineberger 2013 Scientific Retreat.                           May 2013                              


  1. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.  Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  Neuro-oncology.  19(11):1481-1493 Oct 2017.  PMID: 28486691  PMCID:  PMC5737524
  2. McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.  Neuro-oncology.  19(11):1469-1480 Oct 2017.  PMID: 28379424  PMCID:  PMC5737415
  3. Vitucci M*, Irvin DM*, McNeill RS, Schmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AM, Bash RE, Kim S, Berens ME, Miller CR. Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  Neuro-oncology.  19(9):1237-1247 Sep 2017.  *Co-first authors.  PMID: 28398584  PMCID:  PMC5570221
  4. McNeill RS, Irvin DM, Miller CR.  BRAF mutations open doors to ENU-induced gliomagenesis.  American Journal of Pathology.  186(10):2551-2554 Oct 2016.  PMID: 27543966  PMCID: PMC5222976
  5. Schmid RS, Simon JM, Vitucci M, McNeill RS, Bash RE, Werneke AM, Huey L, White KK, Ewend MG, Wu J, Miller CR.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.  Neuro-oncology.  18(7):962-973 Jul 2016.  PMID: 26826202  PMCID: PMC4896545
  6. Irvin DM, McNeill RS, Bash RE, Miller CR.  Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models.  Brain Pathology.  Epub Jan 13, 2016.  DOI: 10.1111/bpa.12348.  PMID: 26762242
  7. McNeill RS, Vitucci M, Wu J, Miller CR.  Contemporary murine models in preclinical astrocytoma drug development.  Neuro-oncology.  17(1):12-28 Jan 2015.  PMID: 25246428  PMCID: PMC4483055
  8. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, Verhaak RGW, Nishiyama A, Miller CR, Zong H.  Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multi-step reactivation process.  Proceedings of the National Academy of Science USA.  111(40):E4214-E4223 Oct 2014.  PMID: 25246577  PMCID: PMC4210043
  9. McNeill RS, Schmid RS, Bash RE, Vitucci M, White KK, Werneke AM, Constance BH, Huff B, Miller CR.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.  Journal of Visualized Experiments.  90:e51763 Aug 2014.  PMID: 25146643.
  10. Vitucci M*, Karpinich NO*, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  *Co-first authors.  Neuro-oncology.  15(10):1317-1329 Oct 2013.  PMID: 23814263  PMCID: PMC3779038
  11. Pathi B, Kinsey ST, Howdeshell ME, Priester C, McNeill RS, Locke BR. The formation and functional consequences of heterogeneous mitochondrial distributions in skeletal muscle. J Exp Biol. 2012 Jun 1;215(Pt 11):1871-83. PMID: 22573766